Table 2. Relationships between RSPO/LGR gene expression and gene expression levels of different pathways of carcinogenesis.
Genes | TNBC with high level of RSPO-LGR mRNA expression (n=44) | TNBC with low level of RSPO-LGR mRNA expression (n=24) | Pa |
---|---|---|---|
Stem cell pathway | |||
CD133 | 1.1 (0.02–7.9) | 0.2 (0.006–5.8) | 0.0045 |
ALDHA1A3 | 0.6 (0.1–11) | 0.4 (0.08–14.2) | 0.37 |
ALDHA1A1 | 0.1 (0.02–0.7) | 0.09 (0.1–0.6) | 0.016 |
EMT pathway | |||
CDH1 | 0.6 (0.01–3) | 0.7 (0.047–5.4) | 0.13 |
VIM | 0.4 (0.15–2.1) | 0.3 (0.02–0.8) | 0.045 |
ZEB1 | 0.3 (0–1.2) | 0.3 (0–0.8) | 0.77 |
ZEB2 | 0.4 (0–1.9) | 0.3 (0–0.9) | 0.2 |
SNAIL | 1.7 (0–8.2) | 1.2 (0–13.1) | 0.54 |
SNAIL2 | 0.6 (0–11.4) | 0.5 (0–3.8) | 0.054 |
TWIST1 | 0.4 (0.05–3.8) | 0.2 (0.04–1) | 0.0047 |
WNT/β-catenin pathway | |||
AXIN2 | 0.35 (0.07–3.6) | 0.2 (0.04–1.3) | 0.048 |
DKK1 | 5.5 (0–786) | 8.8 (2.6–358) | 0.97 |
TCF4 | 0.8 (0–3.6) | 0.6 (0–3) | 0.082 |
LEF1 | 0.3 (0–1.8) | 0.2 (0.02–0.6) | 0.32 |
MMP7 | 3.5 (0–58) | 0.8 (0.02–19) | 0.024 |
Abbreviations: EMT=epithelial–mesenchymal transition; LGR=leucine-rich repeat containing G protein-coupled receptor; TNBC=triple-negtive breast cancer.
Mann–Whitney test.